AR055062A1 - Base cristalina de escitalopram y comprimidos bucodispersables que comprenden una base de escitalopram - Google Patents

Base cristalina de escitalopram y comprimidos bucodispersables que comprenden una base de escitalopram

Info

Publication number
AR055062A1
AR055062A1 ARP060102654A ARP060102654A AR055062A1 AR 055062 A1 AR055062 A1 AR 055062A1 AR P060102654 A ARP060102654 A AR P060102654A AR P060102654 A ARP060102654 A AR P060102654A AR 055062 A1 AR055062 A1 AR 055062A1
Authority
AR
Argentina
Prior art keywords
scitalopram
base
crystalline
escitalopram
free base
Prior art date
Application number
ARP060102654A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546630&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055062(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR055062A1 publication Critical patent/AR055062A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Reiv.1 + Reiv.2 + Rev. 4 + composiciones farmacéuticas que contienen la base cristalina del fármaco escitalopram: S-1-[3-(dimetilamino) propil]-1-(4-fluorofenil)-1,3-dihidro-5-isobenzofuran carbonitrilo, proceso para preparar escitalopram como base libre purificada y sales del mismo, y comprimidos bucodispersables que las contienen. Reivindicacion 1: Escitalopram como base libre en forma solida. Reivindicacion 2: Estacilopram como base libre de acuerdo con la reivindicacion 1 que se caracteriza en que comprende escitalopram cristalino. Reivindicacion 4: Estacilopram como base libre de acuerdo con la reivindicacion 1 que se caracteriza en que es cristalino.
ARP060102654A 2005-06-22 2006-06-21 Base cristalina de escitalopram y comprimidos bucodispersables que comprenden una base de escitalopram AR055062A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200500912 2005-06-22

Publications (1)

Publication Number Publication Date
AR055062A1 true AR055062A1 (es) 2007-08-01

Family

ID=37546630

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060102654A AR055062A1 (es) 2005-06-22 2006-06-21 Base cristalina de escitalopram y comprimidos bucodispersables que comprenden una base de escitalopram
ARP100104958A AR079750A2 (es) 2005-06-22 2010-12-27 Comprimidos bucodispersables y metodo de fabricacion

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP100104958A AR079750A2 (es) 2005-06-22 2010-12-27 Comprimidos bucodispersables y metodo de fabricacion

Country Status (39)

Country Link
EP (3) EP2325177A1 (es)
JP (5) JP4906852B2 (es)
KR (5) KR20110084341A (es)
CN (2) CN101189220A (es)
AR (2) AR055062A1 (es)
AT (3) AT10983U1 (es)
AU (2) AU2006261452B2 (es)
BG (1) BG66086B1 (es)
BR (1) BRPI0612295A2 (es)
CA (2) CA2646780A1 (es)
CY (1) CY1112392T1 (es)
CZ (3) CZ299906B6 (es)
DE (2) DE112006001619T5 (es)
DK (3) DK1896439T4 (es)
EA (2) EA201001108A1 (es)
EE (1) EE00773U1 (es)
ES (2) ES2356838T5 (es)
FI (2) FI20077133A (es)
GB (2) GB2442160B (es)
HR (1) HRP20110093T4 (es)
HU (1) HUP0800135A3 (es)
IL (1) IL187454A0 (es)
IS (1) IS8705A (es)
LT (1) LT5550B (es)
LV (1) LV13677B (es)
MX (1) MX2007015328A (es)
MY (2) MY143239A (es)
NO (2) NO20080359L (es)
PL (2) PL1896439T5 (es)
PT (1) PT1896439E (es)
RS (1) RS51575B2 (es)
SG (1) SG169358A1 (es)
SI (1) SI1896439T2 (es)
SK (1) SK500402007A3 (es)
TR (2) TR200708792T1 (es)
TW (2) TWI347942B (es)
UA (1) UA86536C2 (es)
WO (1) WO2006136169A2 (es)
ZA (2) ZA200711066B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
EP2134325A2 (en) * 2007-03-01 2009-12-23 Aurobindo Pharma Limited Stable solid dosage forms of an antidepressant
ME02391B (me) 2010-07-23 2016-09-20 H Lundbeck As Postupak za prečišćavanje farmaceutski prihvatljivih soli escitaloprama
CN103360353A (zh) * 2013-08-07 2013-10-23 中国药科大学 草酸艾司西酞普兰杂质的制备方法
JP2018016569A (ja) * 2016-07-26 2018-02-01 株式会社トクヤマ （１ｓ）−１−［３−（ジメチルアミノ）プロピル］−１−（４−フルオロフェニル）−１，３−ジヒドロイソベンゾフラン−５−カルボニトリル蓚酸塩の製造方法
WO2018190294A1 (ja) * 2017-04-10 2018-10-18 東和薬品株式会社 エスシタロプラム医薬組成物
CN110711198B (zh) * 2018-07-12 2022-03-15 山东大学 D-甘露糖在制备抗抑郁药物中的应用
KR102331187B1 (ko) 2019-04-09 2021-11-26 주식회사 라이트팜텍 에스시탈로프람을 함유하는 안정성이 우수한 경구용 액제 조성물 및 그의 제조방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
JPH05222041A (ja) * 1992-02-13 1993-08-31 Mitsubishi Gas Chem Co Inc アデニン誘導体の精製法
RU2161954C2 (ru) * 1994-01-27 2001-01-20 Дзе Борд оф Регентс оф Дзе Юниверсити оф Оклахома Быстрорастворяющиеся во рту лекарственные формы
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
AU4655597A (en) 1997-06-30 1999-01-19 Beloit Technologies, Inc. Method and apparatus for the high speed application of coating to a traveling paper web
DE69801764T2 (de) 1997-07-08 2002-07-04 Lundbeck & Co As H Verfahren zur herstellung von citalopram
DE69714480T2 (de) 1997-11-11 2003-03-06 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram
FR2785538B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
US20020071864A1 (en) * 1999-03-25 2002-06-13 Yuhan Corporation Rapidly disintegrable tablet for oral administration
ITMI991581A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
JP2001226372A (ja) * 1999-12-06 2001-08-21 Sumika Fine Chemicals Co Ltd ロサルタンの結晶性または結晶化された酸付加塩およびロサルタンの精製方法
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US7510728B2 (en) * 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
JP4446463B2 (ja) * 2000-10-16 2010-04-07 第一三共株式会社 口腔内速崩壊性医薬組成物およびその製造方法
US7799342B2 (en) 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
TR200201166T1 (tr) * 2000-12-22 2002-10-21 H.Lundbecks A/S Saf sitalopram hazırlanması için yöntem
TR200200018T1 (tr) * 2000-12-28 2002-06-21 H. Lundbeck A/S Saf sitalopram hazırlanması için yöntem.
CA2445843A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
US6872405B2 (en) * 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
GB0113842D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
AR034759A1 (es) 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
TR200400189T2 (tr) * 2001-07-31 2004-12-21 H.Lundbeck A/S Esitalopram içeren kristal yapılı bileşim.
IS7239A (is) 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
US7148364B2 (en) * 2002-01-07 2006-12-12 Sun Pharmaceutical Industries Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
GB0204607D0 (en) * 2002-02-27 2002-04-10 Matrix Lab Ltd Process
EP2228060A1 (en) * 2002-05-03 2010-09-15 Skyepharma Canada Inc. Oral dosage forms comprising fenofibrate
CN100349885C (zh) 2002-12-23 2007-11-21 H·隆德贝克有限公司 依他普仑氢溴酸盐及其制备方法
CN1510024A (zh) * 2002-12-24 2004-07-07 北京德众万全药物技术开发有限公司 可用于制备西酞普兰(s)-对映异构体的新的化合物及其制备方法
DE10305984A1 (de) * 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
AU2004238321B2 (en) * 2003-05-07 2009-08-27 Samyang Biopharmaceuticals Corporation Highly plastic granules for making fast melting tablets
IN234086B (es) * 2003-10-15 2009-05-29 Fuji Chem Ind Co Ltd
WO2005049596A1 (en) * 2003-11-20 2005-06-02 Natco Pharma Limited A process for the preparation of high purity escitalopram
HU227491B1 (en) * 2003-11-25 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Tablet containing citalopram hydrogen bromide
EA200601641A1 (ru) * 2004-03-05 2006-12-29 Х. Лундбекк А/С Кристаллическая композиция, содержащая оксалат эсциталопрама
WO2006106531A1 (en) * 2005-04-04 2006-10-12 Jubilant Organosys Ltd Process for the preparation of escitalopram or its acid addition salts

Also Published As

Publication number Publication date
CZ301286B6 (cs) 2009-12-30
WO2006136169A2 (en) 2006-12-28
SI1896439T2 (sl) 2014-12-31
TR200708792T1 (tr) 2008-05-21
TW200740785A (en) 2007-11-01
GB2442160B (en) 2010-01-20
BG66086B1 (bg) 2011-03-31
DK1896439T4 (en) 2015-01-12
KR20110033310A (ko) 2011-03-30
HRP20110093T1 (hr) 2011-03-31
CZ300686B6 (cs) 2009-07-15
FI20077133A (fi) 2007-12-20
WO2006136169A3 (en) 2007-10-18
KR20100133023A (ko) 2010-12-20
RS51575B2 (sr) 2018-02-28
ES2319073B1 (es) 2010-02-26
LT5550B (lt) 2009-03-25
CN101928269A (zh) 2010-12-29
ES2356838T3 (es) 2011-04-13
ATE497500T1 (de) 2011-02-15
ES2356838T5 (es) 2015-01-26
AT11883U1 (de) 2011-06-15
DE112006001619T5 (de) 2008-06-12
JP2009179634A (ja) 2009-08-13
HUP0800135A3 (en) 2009-01-28
ZA200901698B (en) 2010-04-28
TW201130808A (en) 2011-09-16
LT2008005A (en) 2008-10-27
AT10983U1 (de) 2010-02-15
AU2006261452A1 (en) 2006-12-28
NO20101777L (no) 2008-01-18
EE00773U1 (et) 2008-10-15
EP1896439A2 (en) 2008-03-12
CZ2007898A3 (cs) 2008-01-23
GB2448834A (en) 2008-10-29
ZA200711066B (en) 2009-07-29
JP4415056B2 (ja) 2010-02-17
AU2010200844A1 (en) 2010-04-01
CA2646780A1 (en) 2006-12-28
NO20080359L (no) 2008-01-18
JP2008546724A (ja) 2008-12-25
GB0811164D0 (en) 2008-07-23
CA2612827A1 (en) 2006-12-28
JP2009046506A (ja) 2009-03-05
EA019239B1 (ru) 2014-02-28
EP1896439B1 (en) 2011-02-02
IS8705A (is) 2008-01-14
EA201001108A1 (ru) 2011-02-28
GB2442160A (en) 2008-03-26
CY1112392T1 (el) 2015-12-09
UA86536C2 (ru) 2009-04-27
MY143239A (en) 2011-04-15
PT1896439E (pt) 2011-02-15
ES2319073A1 (es) 2009-05-01
JP2012072168A (ja) 2012-04-12
EP1896439B2 (en) 2014-10-15
KR20120064140A (ko) 2012-06-18
CZ299906B6 (cs) 2008-12-29
DK200900284A (da) 2009-02-27
TWI347942B (en) 2011-09-01
CA2612827C (en) 2010-11-30
KR20110084341A (ko) 2011-07-21
DE602006019961D1 (de) 2011-03-17
HRP20110093T4 (hr) 2015-02-27
CN101189220A (zh) 2008-05-28
AR079750A2 (es) 2012-02-15
TWI358407B (en) 2012-02-21
GB2448834B (en) 2010-01-20
KR101340815B1 (ko) 2013-12-11
EP2385044A1 (en) 2011-11-09
BRPI0612295A2 (pt) 2011-01-04
DK1896439T3 (da) 2011-02-28
PL1896439T5 (pl) 2016-01-29
SI1896439T1 (sl) 2011-03-31
KR20080018191A (ko) 2008-02-27
RS51575B (en) 2011-08-31
TR201000625T1 (tr) 2010-03-22
MX2007015328A (es) 2008-02-15
FI20080548A (fi) 2008-10-07
HUP0800135A2 (en) 2008-06-30
LV13677B (en) 2008-05-20
EA200800102A1 (ru) 2008-04-28
SK500402007A3 (sk) 2008-05-06
MY143252A (en) 2011-04-15
BG110024A (bg) 2008-05-30
JP4906852B2 (ja) 2012-03-28
EP2325177A1 (en) 2011-05-25
GB0724557D0 (en) 2008-01-23
JP5731957B2 (ja) 2015-06-10
PL384185A1 (pl) 2008-06-23
JP2009179635A (ja) 2009-08-13
IL187454A0 (en) 2008-02-09
SG169358A1 (en) 2011-03-30
AU2006261452B2 (en) 2010-02-04
DK200800075A (da) 2008-03-15
PL1896439T3 (pl) 2011-04-29

Similar Documents

Publication Publication Date Title
AR055062A1 (es) Base cristalina de escitalopram y comprimidos bucodispersables que comprenden una base de escitalopram
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
EA201200506A1 (ru) СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ)БЕНЗОЛА
ECSP066376A (es) FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
AR054846A1 (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4- piridin-3-il-pirimidin-2- ilamino)-benzamida
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
EA200702253A1 (ru) Фармацевтическая композиция
EA201270505A1 (ru) Производные иминотиадиазиндиоксида в качестве ингибиторов bace, композиции на их основе, и их применение
CU23551B7 (es) Procedimiento para la producción de una composición farmacéutica sólida de administración oral
ATE465719T1 (de) Oral zerfallende zusammensetzung von olanzapin oder donepezil
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
EA200702329A1 (ru) Замещенные пирролпиридины, содержащие их композиции, способ получения и применение
CL2008001157A1 (es) Compuestos derivados de quinolina-carboxamida, antagonistas de p2y12; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; composicion de una combinacion de dichos compuestos; y uso del compuesto en el tratamiento de trastornos cardiovasculares, tromboembolismo, infarto agudo al miocardio.
ECSP066715A (es)
BRPI0815134A2 (pt) Processo para a preparação de olmesartana medoxomila
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
CY1112725T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
CL2011001098A1 (es) Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras.
CO6020017A1 (es) Forma galenica divisible que permite una liberacion modificada del principio activo
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
EA201170512A1 (ru) Композиция для перорального введения
EA201691869A1 (ru) Стабильная комбинированная фармацевтическая композиция
ME00955B (me) Kompozicija sa produženim oslobađanjem koja sadrži derivat somatostatina u mikročesticama

Legal Events

Date Code Title Description
FA Abandonment or withdrawal